Converting enzyme inhibition with captopril in patients with primary hyperaidosteronism

John R. Luderer, Laurence M. Demers, Timothy S. Harrison, Arthur H. Hayes

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


The humoral and hemodynamic effects of converting enzyme inhibition with captopril are presented in two patients with primary hyperaldosteronism (PHA). In all, 20 patients with resistant hypertension were treated with the angiotensin converting enzyme inhibitor captopril. In 18 patients with essential or renovascular hypertension mean (±SEM) plasma renin activity (PRA) rose from 5.0 ± 1.4 to 35.3 ± 5.3 ng/ml/hr (P < 0.001) and mean (±SEM) plasma aldosterone (PA) declined from 25.8 ± 2.9 to 15.1 ± 1.9 nglml (P < 0.01) after captopril. In two patients with PHA the PRA was not stimulated by converting enzyme inhibition, although there was modest decline in PA and a temporary reduction in blood pressure. After surgical removal of aldosterone-producing adenomas, PRA responsed appropriately to captopril. These cases illustrate that a disease process can modify the response to a drug and demonstrate that, in patients with PHA, captopril does not stimulate PRA, induces only minor decrements in PA, and is relatively ineffective as an antihypertensive.

Original languageEnglish (US)
Pages (from-to)305-311
Number of pages7
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Mar 1982

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Converting enzyme inhibition with captopril in patients with primary hyperaidosteronism'. Together they form a unique fingerprint.

Cite this